Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcomas
- 1 May 2023
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in American Society of Clinical Oncology Educational Book
- Vol. 43 (43) , e390306
Abstract
Bone sarcomas are rare heterogeneous tumors that affect patients of all ages including children, adolescent young adults, and older adults. They include many aggressive subtypes and patient groups with poor outcomes, poor access to clinical trials, and lack of defined standard therapeutic strategies. Conventional chondrosarcoma remains a surgical disease, with no defined role for cytotoxic therapy and no approved targeted systemic therapies. Here, we discuss promising novel targets and strategies undergoing evaluation in clinical trials. Multiagent chemotherapy has greatly improved outcomes for patients with Ewing sarcoma (ES) and osteosarcoma, but management of those with high-risk or recurrent disease remains challenging and controversial. We describe the impact of international collaborative trials, such as the rEECur study, that aim to define optimal treatment strategies for those with recurrent, refractory ES, and evidence for high-dose chemotherapy with stem-cell support. We also discuss current and emerging strategies for other small round cell sarcomas, such as CIC-rearranged, BCOR-rearranged tumors, and the evaluation of emerging novel therapeutics and trial designs that may offer a new paradigm to improve survival in these aggressive tumors with notoriously bad (to the bone) outcomes.Keywords
This publication has 173 references indexed in Scilit:
- Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcomaNature Genetics, 2013
- Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiationAnnals of Oncology, 2012
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- Identification of a novel, recurrent HEY1‐NCOA2 fusion in mesenchymal chondrosarcoma based on a genome‐wide screen of exon‐level expression dataGenes, Chromosomes and Cancer, 2011
- Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput ScreeningJNCI: Journal of the National Cancer Institute, 2011
- IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumoursThe Journal of Pathology, 2011
- Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocolAnnals of Oncology, 2010
- Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European groupEuropean Journal of Cancer, 2007
- Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcomaPediatric Transplantation, 2005
- The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the ExtremityNew England Journal of Medicine, 1986